In the present study, we identified differential expression of immunoreactive matrix metalloproteinase MMP2/ gelatinase A, membrane-anchored MT1-MMP/ MMP14, and human relaxin-2 (RLN2) in human benign and malignant thyroid tissues. MMP2 and MT1-MMP were detected in the majority of thyroid cancer tissues and co-localized with RLN2-positive cells. MMP2 was mostly absent in goiter tissues and, similar to RLN2, may serve as a marker for thyroid cancer. MMP2 and MT1-MMP were identified as novel RLN2 targets. RLN2 caused a significant down-regulation of tissue inhibitor of MMP (TIMP) 3 protein levels but did not change the expression levels of MMP13, and TIMP1, TIMP 2, and TIMP4 in human thyroid carcinoma cells. RLN2 failed to affect the expression of MMP1, 3, 8, 9 in the thyroid carcinoma cells investigated. Stable RLN2 transfectants secreted enhanced levels of bioactive MMP2 which contributed to the increased collagenolytic activity and in-vitro invasiveness into collagen matrix by human thyroid cancer cells. Three dimensional reconstitution of confocal fluorescent microscopy revealed larger sized invadopodia with intense MT1-MMP accumulation at the leading migrating edge in RLN2 transfectants when compared to EGFP clones. In RLN2 transfectants actin stress fibers contributed to pseudopodia formation.
INTRODUCTION
The multifunctional heterodimeric peptide hormone relaxin, a member of the insulin-like superfamily, is an established endocrine factor in the reproductive tract, cardiovascular/ neural system and in cancer biology (1) (2) (3) (4) (5) (6) . Up-regulated in various human cancer tissues, RLN2 contributes to tumor cell proliferation, tissue invasion, and tumor angiogenesis (7) (8) (9) . Understanding the molecular mechanisms by which RLN2 enhances the tissue invasiveness of tumor cells in patients is of prognostic and therapeutic importance. High serum levels of RLN2 were shown to be associated with increased levels of metastasis in breast cancer patients (10) .
The penetration of the basal lamina and remodeling of the extracellular matrix (ECM) are crucial early steps in the process of tumor cell invasion. Relaxin is known to contribute to ECM remodeling processes in various biological systems by: (i) inhibiting fibroblast proliferation and differentiation (11, 12) ; (ii) inhibiting collagen synthesis/ secretion and tissue deposition in vivo (13-15); (iii) altering the composition and structural integrity of the ECM (16) (17) (18) (19) ; and by (iv) increasing the production/ secretion and activity of enzymes that are powerful remodeling factors of the basal lamina and ECM (20, 21) . In the human thyroid gland, RLN2 is exclusively detected in thyroid cancer tissues and enhances the production and secretion of the lysosomal acid hydrolases of the cathepsin family which promote penetration of elastin matrices by human thyroid cancer cells (7) . Earlier reports supported a role for relaxin in ECM remodeling by up-regulating cathepsin B and dipeptidyl peptidase I in the mouse pubic symphysis and urokinaseand tissue type plasminogen activator in the uterus and cervix of prepubertal gilts (22) (23) (24) . Members of the family of matrix metalloproteinases (MMPs) and their tissue inhibitors of MMP (TIMP1-4) are another group of proteinases responsive to relaxin.
The MMP/TIMP system is known to modulate normal (e.g., development, growth, repair) and pathological tissue compositions (e.g., fibrosis, tumor spread). Functional imbalance between MMPs and TIMPs can facilitate tumor cell invasion of basal lamina and ECM and enhances tumor angiogenesis (25) . The members of the human MMP family of zincdependent endopeptidases segregate into five major subclasses (collagenases, stromelysins, gelatinases, membrane-type MMPs, other MMPs) (26) . All of these MMPs combined have the ability to degrade essentially any ECM component (27) . Apart from the basic structural design of secreted MMPs, which includes an N-terminal signal peptide, a propeptide, and a catalytic domain with a conserved zinc binding site linked to a hemopexin-like domain, the membrane-type(MT)-MMPs 1-4 possess an additional anchoring transmembrane and cytoplasmic domain C-terminal to the hemopexin-like domain. MMP family members MMP2 and MT1-MMP, for example, not only degrade ECM components but can also cleave and activate growth factors, thereby promoting tumor cell migration/invasion (28, 29) and modulating angiogenesis (30) .
MMP2, MT1-MMP, and TIMP2 play a significant role in thyroid cancer. These MMP and TIMP members are frequently up-regulated in differentiated thyroid carcinoma and increased MMP2 expression is common in papillary and undifferentiated/ anaplastic thyroid cancer, but not in follicular adenoma (31) (32) (33) . Enhanced production and activation of proMMP2, MT1-MMP, and TIMP2 is positively associated with large thyroid tumor size, increased invasiveness, including lymph node metastasis, and advanced disease stage (31, 34, 35) . Human normal thyrocytes and thyroid carcinoma cell lines were shown to express MMP1, 2, 9, MT1-MMP, and TIMP1-3. (36, 37) .
Relaxin affects the expression and/or secretion of collagenase 1 (MMP1) and 3 (MMP13), gelatinase A (MMP2) and B (MMP9), stromelysin1 (MMP3), and MT1-MMP in the periodontal apparatus and joints (38) (39) (40) , lung (13), reproductive tissues (24, (41) (42) (43) , human renal fibroblasts (44) , and human breast cancer cells (20) . We previously showed that human thyroid cancer tissue is a source of RLN2 and that RLN2 enhances elastin matrix degradation by thyroid cancer cells (7) .
In the present study, we have determined the tissue distribution of MMP2/ gelatinase A and MT-MMP1/ MMP14 in human thyroid carcinoma tissues and identified MMP2 to be predominantly present in thyroid tumor tissues. We show that both MMPs are RLN2 target molecules in thyroid carcinoma cells. Of all members of the TIMP family, RLN2 caused no changes in TIMP2 but a significant down-regulation of TIMP3 in thyroid cancer cells. The RLN2-mediated up-regulation of in-vitro invasiveness through collagen matrices coincided with the increased presence of MT1-MMP and MMP2 at the leading migrating edge of invadopodia in human thyroid carcinoma cells. These findings implicate the MMP2 -MT1-MMP -TIMP2 system and TIMP3 as potent mediators of RLN2 in promoting tissue invasion and angiogenesis in human thyroid cancer. 
MATERIALS AND METHODS

Reverse transcriptase Polymerase chain reaction (RT-PCR)
One microgram of total RNA was used as a template for first strand cDNA synthesis as described previously (7) . PCR amplification conditions had been optimized for each primer pair listed in Table I .
Tissues
A total of 106 human thyroid tissues (25 goiter, 30 papillary (PTC), 27 follicular (FTC), 24 undifferentiated thyroid cancer (UTC)) were obtained at the Department of General, Visceral and Vascular Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany (Table II) . Tumour size, local tissue invasion, colonization of local lymph nodes, and presence/ absence of metastases were determined according to the pTNM tumor staging classification (T=tumor, N=lymph node, M=metastasis). Tissue specimens were cryopreserved in liquid nitrogen. Human placental tissue sections were used as positive control for the immunodetection of MT1-MMP. The collection of all human tissues studied was approved by the ethical committee at the Martin Luther University, Faculty of Medicine, and all patients gave written consent.
Cell culture
The human follicular thyroid carcinoma cell line FTC-133 and previously described FTC-133 stable transfectants expressing human RLN2 (FTC-133-RLN2) and EGFPexpressing FTC-133 negative controls (FTC-133-EGFP) (7, 45) were cultured in DMEM/ HAM-F12 medium plus 10% fetal calf serum (FCS; Gibco, Berlin, Germany). Culture medium was changed every 2-3 days and transfectants were passaged every 5-6 days.
Prior to the experiments, cells were either seeded in 25 cm 2 flasks or in 6-, 24-or 96-well plates (Techno Plastic Products AG, Trasadingen, Switzerland) at 80% confluency.
Untransfected FTC-133 at the same concentration were incubated with 100 ng/ ml RLN2 (RLN2 was generously provided by Corthera Inc., USA). All experiments were performed under serum-free conditions.
Immunohistochemistry
For immunohistochemistry, sections of goiter and thyroid carcinoma tissues were investigated for the presence of immunoreactive MMP2, MT1-MMP, and RLN2.
Immunohistochemical analysis was performed using the DAKO LSAB Kit (Dako, Cambridgeshire, UK). Tissue sections were fixed with 3% H 2 O 2 in cold methanol for 25 min, washed in PBS plus 0.1% Tween-20 (PBST), and non-specific binding sites were blocked with 10% goat serum in PBST (blocking buffer) for 1 h at RT. Sections were incubated with the primary monoclonal antibodies for MMP2 and MT1-MMP (both Calbiochem, Darmstadt, Germany) diluted 1:100, or a polyclonal antiserum against RLN2 (Immunodiagnostik, Bensheim, Germany) at 1:300 with antibody diluent (Dako) at 4°C overnight (7) . Sections were incubated with horse radish peroxidase-(HRP-) conjugated secondary antibodies (Dako) for colorimetric detection of target MMPs and RLN2 within the thyroid tissues investigated. Immunostained sections were counterstained with hematoxylin/ eosin.
Immunofluorescence and confocal laser scanning microscopy
The day before the immunofluorescence experiments, cells were washed twice with 1x PBS and grown in serum-free medium overnight. For exclusive F-actin staining, cells 
Pseudopodia assay
Pseudopodia assays were performed with slight modifications as described previously (47) . The day before the assay, cells were washed twice with 1X PBS and grown in all Sigma) for 10 seconds. The remaining cell body was collected by adding 100 µl of lysis buffer onto the top of each filter. Pseudopodia and cell body lysates from three filters were pooled, separately, and subjected to three freeze/ thaw cycles (dry ice for 3 min and thawed at 37 °C for 1 min). Lysates were centrifuged at 13,000 x g for 20 min at 4°C and supernatants of pseudopodia lysates were dried in a SpeedVac, resuspended in double distilled water to make a 10x concentrated pseudopodia supernatant and protein concentration was measured using the Micro BCA Protein Assay Kit (Pierce, ON, Canada). Proteins from the cell body and the pseudopodia were separated on a 12% gradient gel (Invitrogen) and transferred to nitrocellulose membranes (Thermo Fisher) for the detection of MMP2 and MT1-MMP.
MMP2/MMP9 activity assay
The enzymatic activity of secreted MMP2 derived from stable FTC-133 transfectants and untransfected FTC-133 was determined using the MMP2/ MMP9 activity test 
Statistical analysis
Statistical analysis was carried out with SPSS 12.0 and Excel software and all experimental parameters were calculated for statistical significance using Student's ttest. p< 0.05 were considered statistically significant. Densitometric analysis was carried out using the Kodak Digital Science 1D software. 
RESULTS
Immunoreactive MT1-MMP and MMP-2 are increased and co-localize with RLN2 in human thyroid carcinoma
We analysed human goiter tissues and PTC, FTC, and UTC thyroid cancer tissues for the presence of immunoreactive MMP2, MT1-MMP, and RLN2. Goiter tissues showed very weak to absent immunostaining for MMP2 (Fig. 1A) , MT1-MMP (Fig. 1C) and RLN2 (Fig. 1E) . Only 1 of 15 (7%) and 3 of 10 (30%) of goiter cases showed weak staining for MMP2 and MT1-MMP, respectively. None were positive for RLN2 as described previously (7). All thyroid carcinoma tissues investigated (PTC, FTC, UTC) displayed increased presence of immunoreactive MMP2 (Fig. 1G, M, S) , MT1-MMP (Fig. 1I, O, U) , and RLN2 (Fig. 1K, Q, W) . When the specific antiserum was replaced with a non-immune serum of the same species, no specific immunostaining was obtained in any of the tissues (Fig. 1B, D, F , H, J, L, N, P, R, T, V, X). RLN2 colocalized with MMP2-and MT1-MMP-producing cells. We were unable to find a correlation for immunoreactive MMP2 or MT1-MMP thyroid cancer tissues with either gender, age, or tumor size, lymphatic/ systemic metastasis (pTNM) status of the patients (Table II) . No correlation with these clinicopathological criteria was found for the presence of both MMP2 and MT1-MMP in the few thyroid cancer tissue cases (3 PTC, 6 FTC, 5 UTC) which we were able to test for both MMPs ( Table II) . The immunohistochemical staining results suggested that MMP2 may be a suitable marker for thyroid cancer since only a minority of goiter tissue (<10%) but a high percentage (61-77%) of thyroid cancer tissues expressed immunoreactive MMP2. MT1-MMP was present in both goiter (30%, weak staining) and thyroid cancer tissues (67-82%) ( Table III) MT1-MMP and MMP2 were present in fetal trophoblast cells of human placenta used as positive control (data not shown) (48) .
RLN2 enhances the expression of MMP2 and MT1-MMP
We show that RLN2 increased the transcriptional activity, protein production, and secretion of gelatinase A/ MMP2 in previously described RLN2 expressing stable transfectants of the human follicular thyroid carcinoma FTC-133. MT1-MMP protein in either the 64 KDa proform ( Fig. 2A) and 54 kDa active form (Fig. 2B) were up-regulated in two out of three or all three RLN2 transfectants, respectively, when compared to the EGFP control. All RLN2 clones, but not the EGFP mock, displayed strong immunoreactive bands at 72 kDa corresponding to MMP2 (Fig. 2C) . TIMP2 is part of an MMP2 activation complex, which also includes proMMP2 and MT1-MMP (49) . The expression of TIMP2 detected as a single immunoreactive protein at 21 kDa did not change significantly in all EGFP and RLN2 clones tested (Fig. 3D) . The expression levels determined for MT1-MMP, MMP2, and TIMP2 correlated well with the densitometric measurements derived from the Western blot analysis for MT1-MMP proform (64 kDa) and active form (54 kDa), MMP2, and TIMP2 (data not shown). The upregulation in MT1-MMP and MMP2 correlated with RLN2 production as determined by RLN2 ELISA in the FTC-133-RLN2 stable transfectants (70-95 pg/ml) and negligible levels of RLN2 in the EGFP mock cells (data not shown).
Of the four TIMP protein members identified by Western blot in the FTC-133 transfectants, RLN2 caused an exclusive and marked reduction in TIMP3 isoforms at 48 kDa (Fig. 2E ) and 27 kDa (Fig. 2F) , without affecting the levels of TIMP1 or TIMP4 protein ( Table IV) . Expression of other members of the MMP family known to be was tested in the FTC133-EGFP and FTC133-RLN2 transfectants using RT-PCR.
Transcripts were exclusively observed for MMP13 and remained unaltered in the presence of RLN2 (Table IV) . FTC-133 cells were devoid of MMP1, 3, 8, 9, and 10 transcripts ( Table IV) .
RLN2 enhances secretion of active MMP2 and collagenolytic activity by human thyroid cancer cells
Supernatants of RLN2 transfectants contained significantly more bioactive MMP2 when compared to the mock control as determined by MMP2/ MMP9 bioactivity assay (Fig.   3A) . The enzymatic processing of the substrate was likely caused by the increased MMP2 activity since RLN2 transfectants did not express MMP9 ( Table IV) . The addition of the general MMP inhibitor GM6001 abolished the enhanced proteolytic cleavage of the fluorescently labelled substrate by the RLN2 transfectants, but not mock transfectants (Fig. 3C) . Untransfected FTC-133 thyroid cancer cells exposed to recombinant RLN2 also showed enhanced secretion of active MMP2 (Fig. 3B) . Further, protein extracts of RLN2 transfectants (clone 10) subjected to in-gel collagen-I zymography revealed a specific band of digested collagen-I at 72 kDa likely resembling MMP2 (Fig. 3D) . In-situ zymography assays also demonstrated that the transfectants cultured in gelatine matrices differed in their ability to degrade this matrix as evidenced by the larger bright peri-cellular halos around RLN2 transfectants, which could be inhibited with the general MMP inhibitor GM6001 at a concentration known to inhibit MMP2 (Fig. 3E) . 
RLN2 increases migration through collagen matrix and recruitment of MT1-MMP to the leading edge of migration in human follicular thyroid cancer cells
We performed migration assays to determine if the observed increase in MMP2 and MT1-MMP production and MMP2 activity resulted in enhanced penetration of the RLN2 transfectants through collagen type I matrices. All three RLN2 transfectants tested (Fig.   4A ) and FTC-133 cells treated with human recombinant RLN2 (Fig. 4B) were able to penetrate collagen-I matrix and migrate to the underside of the filter in significantly higher numbers than mock and untreated controls, respectively. In addition to collagen I, MMP2 and MT1-MMP are capable of digesting other extracellular matrix compounds, including gelatine and fibronectin (50) . We observed a positive trend, but no significant increase, in migration through gelatine matrices and no change in the ability of clones to invade fibronectin matrix (data not shown).
To further elucidate the potential mechanism by which RLN2 may facilitate the enhanced migration of thyroid cancer cells through collagen matrices, we isolated pseudopodial membrane protrusions extending into 1 μm wide filter pores after a 1 h migration time.
The narrow filter pores only permitted the collection of invadopodia rather than the whole cell body which stayed on top of the filter as shown by the exclusive presence of the nuclear protein lamin A/C in protein preparations from the top, but not the bottom, of the filter (Fig. 4C) . This pseudopodia assay allowed us to determine proteins present at the leading edge of migration (bottom of filter) and the rest of the cell body (top of filter).
Western blot analysis of protein extracts from the invadopodia (bottom of filter) and rest of the cell body (top of filter) confirmed the increased overall production of MT1-MMP in RLN2 clones as compared to EGFP clones (data not shown; Fig. 2A, B) . Protein levels (Fig. 4C, D) . Next, we employed multicolour fluorescent confocal microscopy on RLN2 and EGFP transfectants to visualize the presence of MT1-MMP in invadopodia invading the 3 μm wide filter pores. A monoclonal antibody against beta1 integrin was used as a membrane marker. We observed pronounced immunofluorescent staining for both MT1-MMP and beta1 integrin in the invadopodia of RLN2 clones when compared to EGFP clones at the same exposure time (Fig. 5A) . Thus, one way of RLN2 to ensure increased collagen invasion was to increase the concentration of MT1-MMP within the cells and the invadopodia as compared to EGFP clones. In the invadopodia, though, MT1-MMP was distributed over a much smaller surface area (Fig. 5A ) and, thus, was more concentrated as shown in the confocal fluorescent images of the membrane pore-penetrating invadopodia (Fig. 5A) . RLN2 may alter the actin cytoskeleton and this may contribute to the increased invasion of extracellular matrices (ECM). Staining of F-actin by the fungal toxin phalloidin revealed distinct differences in the actin cytoskeletal organization in EGFP and RLN2 transfectants, with the latter displaying stress fibers (Fig. 5B) . Increased stress fiber formation was also detected in the 3D confocal images of invadopodia derived from the RLN2 transfectants (Fig. 5C), suggesting changes to the cytoskeletal actin architecture and increased presence of finding of an up-regulation of MT1-MMP/ MMP2 coincided with the RLN2-induced downregulation of TIMP3. TIMP3 is known to inhibit vascular endothelial growth factor (VEGF)-mediated angiogenic signalling and lack of TIMP3 has been shown to cause an increase in abnormal vessel formation (62) . Our findings may in part explain the increased angiogenesis and growth we had reported previously in xenografts derived from the FTC-133 transfectants expressing RLN2 used in this study (7) .
Currently, few factors have been identified which can affect the expression of MMP2 and MT1-MMP. Epidermal growth factor (EGF) was shown to mediate the invasion of differentiated thyroid cancer cells by an EGF receptor mediated increase in the expression and activation of MMP2 (35) . The membrane-bound glycoprotein and MMP1 receptor EMMPRIN (extracellular matrix metalloproteinase inducer, CD147) was reported to induce MMP1, 2, 3, and MT1-MMP, but not MMP9 expression (63) . Here, we have identified RLN2 as novel potent inducer of MMP2 and MT1-MMP in human follicular thyroid cancer cells. RLN2 is strongly and specifically expressed in thyroid cancer tissues and both relaxin receptors, RXFP1 and RXFP2, are expressed in the thyroid gland (7, 64, 65) . Exposure to RLN2 caused a significant RXFP1-mediated increase in the ability of human thyroid cancer cells to invade elastin matrices as a result of the enhanced production and secretion of cathepsin-L, a potent elastinolytic lysosomal hydrolase (7). Our discovery of MMP2 and MT1-MMP as novel RLN2 targets in human thyroid cancer cells identifies RLN2 as an important multifunctional regulator of a range of potent proteases with overlapping ECM-degrading qualities known to facilitate various stages of (thyroid) cancer cell invasiveness (35, (66) (67) (68) . Relaxin exerts autocrine/ paracrine actions on tumor cell migration/ invasion and angiogenesis in different human cancer models (1, 5) . Follicular thyroid cancer cells and PC-3 prostate carcinoma cells expressing RLN2 displayed enhanced xenograft growth and angiogenesis (7, 69, 70) . The importance of the relaxin/ RXFP1 ligand receptor system for tumor growth is also highlighted by two sets of in-vivo experiments. We and others have recently shown that the intratumoral injection of a relaxin antagonist peptide 
Currently, little information is available on the local effects RLN2 in tumor cells and tissues. The MMP2/ MT1-MMP/ TIMP2 complex and α V β 3 integrin were reported to localize to specific caveolin microdomains, invadopodia, at the leading edge of migration (77, 78) . This prompted us to elucidate the effects of RLN2 on the local distribution of MT1-MMP at the leading edge of migration in human follicular thyroid carcinoma cells.
Pseudopodia assays resemble a modified motility assay with the ability to isolate cell components exclusively derived from the invading membrane tip of motile cells (47) . We combined pseudopodia assays with Western blot analysis and confocal fluorescent microscopy to gain quantitative and visual information on the distribution of MT1-MMP at the leading migrating edge. The higher level of immunoreactive MT1-MMP in the RLN2 transfectants caused more MT1-MMP to be concentrated in the small volume of the invadopodia, likely contributing to high local levels of collagenolytic activity with resulting more effective collagen matrix degradation by RLN2 transfectants as compared to the EGFP clones. This "extrinsic" effect of RLN2 which affected the proteolytic activity at the leading migrating edge of tumor cells and resulted in ECM remodeling in the pericellular space was not the only mechanism employed by this hormone to promote tumor cell invasion. Exclusive to the RLN2 transfectants and not observed in EGFP clones, RLN2 also facilitated invasion of thyroid cancer cells by an "intrinsic" mechanism that promoted the formation of actin stress fibers by an as yet unidentified mechanism. Confocal images revealed that these actin stress fibers participated in the formation of the invadopodia in RLN2 transfectants. The remodeling of the actin cytoskeletal architecture and formation of bundles of actomyosin stress fibers are important steps in invadopodia formation and facilitate cell migration and ECM degradation (72, 79 
In summary, the specific up-regulation and co-localization of RLN2, MT1-MMP, and MMP2 in human thyroid cancer tissues as well as the contribution of RLN2-induced actin stress fibers to the formation of MT1-MMP-rich invadopodia that cause local collagenolytic remodeling of the surrounding ECM microenvironment identifies RLN2 as a novel and versatile pathogenic factor in thyroid cancer invasiveness. clones. MMP13 (collagenase-3) transcripts but were not altered between RLN2 and EGFP clones.
Matrix-Metalloproteinase (MMP)
MMP1
Negative
MMP2
Up-regulated in RLN2 clones
MMP3 Negative
MMP8 Negative
MMP9 Negative
MMP10 Negative
MMP13
Present but unchanged
MMP14
Up-regulated in RLN2 clones
Tissue Inhibitors of MMP (TIMP)
TIMP1
Present but unchanged
TIMP2
Present but unchanged
TIMP3
Down-regulated in RLN2 clones
TIMP4
Present but unchanged
